MyVisionTest News Archive

Displaying news items tagged with Lucentis (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Intravitreal injection
Jan 16, 2011
Researchers studied choroidal neovascularization recurrence interval times in patients with neovascular age-related macular degeneration (AMD) after intravitreal anti-VEGF therapy. Individualized anti-VEGF dosing that aims to avoid recurrent CNV activity as well as additionally to further reduce the number of injections and visits would aim to...

Full Article


Highway traffic
Nov 22, 2010
Patients with neovascular age-related macular degeneration (AMD) who receive monthly intravitreal injections of Lucentis (ranibizumab), a vascular endothelial growth-factor (VEGF) antagonist, are likelier to continue driving and to report less difficulty driving than patients who receive sham injections, a new study shows. The study's lead...

Full Article


Laser eye surgery
Oct 25, 2010
A combination of photodynamic therapy (PDT) plus intravitreal Lucentis (ranibizumab) can achieve visual results in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) similar to those of Lucentis monotherapy with fewer retreatments, according to a new study. Despite success in treating leakage from new...

Full Article


Central retinal vein occlusion
Oct 25, 2010
For the better part of the last 2 decades, there has been little debate as to the preferred treatment of retinal vein occlusion. Ever since the results of the Branch Vein Occlusion Study were published in 1984, gold standard therapy has called for grid laser photocoagulation to treat vision-reducing macular edema caused by branch retinal vein...

Full Article


Intravitreal injection
Oct 24, 2010
Avastin (bevacizumab) and Lucentis (ranibizumab) use was not associated with increased risks of mortality, myocardial infarction, bleeding, or stroke compared with photodynamic therapy or Macugen (pegaptanib) use. Before June 2006, the approved pharmacologic therapies for neovascular age-related macular degeneration (AMD) in the United States...

Full Article


Age-related macular degeneration
Oct 21, 2010
Paperwork delays in getting approval for Lucentis (ranibizumab) therapy of neovascular age-related macular degeneration (AMD) in Germany can lead to vision loss, according to a new study. In Germany, Lucentis treatment is usually covered by the public health insurance only after reviewing each individual case. In addition, health insurance...

Full Article


Central retinal vein occlusion
Oct 16, 2010
Monthly Lucentis (ranibizumab) significantly increased best-corrected visual acuity (BCVA) and decreased macular edema, compared with sham, in patients with central retinal vein occlusion (CRVO), according to a new study. Until recently, there has been no effective therapy for macular edema secondary to central retinal vein occlusion (CRVO)....

Full Article


Visudyne
Oct 14, 2010
Triple therapy with intravitreal Avastin (bevacizumab) or Lucentis (ranibizumab), dexamethasone and verteporfin photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) results in fewer retreatments than either Avastin or Lucentis alone, according to a new study. No single therapy completely addresses all of the ways...

Full Article


Laboratory glassware
Sep 21, 2010
VEGF antagonists, such as Avastin (bevacizumab) and Lucentis (ranibizumab), impair the barrier function of cultured retinal pigment epithelium (RPE) cells, according to a new study. In spite of the favorable results of anti-VEGF therapies in the treatment of exudative age-related macular degeneration (AMD), several adverse incidents are related...

Full Article


Macular degeneration
Sep 20, 2010
Retrospective analysis of potential prognostic factors may help clinicians understand which patients with age-related macular degeneration are likely to respond well to anti-VEGF therapy, a speaker said at the Euretina meeting. "Anti-VEGF treatment has changed dramatically the prognosis of AMD. In most cases, visual acuity will not decrease...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More